Adherence and barriers to hyperinsufflation in children with congenital muscular dystrophy.

about

Adherence and barriers to hyperinsufflation in children with congenital muscular dystrophy.

Item

http://www.wikidata.org/entity/Q39164057

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Adherence and barriers to hype ...... congenital muscular dystrophy.

@en

Adherence and barriers to hype ...... congenital muscular dystrophy.

@nl

type

Item

label

Adherence and barriers to hype ...... congenital muscular dystrophy.

@en

Adherence and barriers to hype ...... congenital muscular dystrophy.

@nl

prefLabel

Adherence and barriers to hype ...... congenital muscular dystrophy.

@en

Adherence and barriers to hype ...... congenital muscular dystrophy.

@nl

P1476

Adherence and barriers to hype ...... congenital muscular dystrophy

@en

P2093

Anne M Rutkowski

http://www.w3.org/2001/XMLSchema#string

Avani C Modi

http://www.w3.org/2001/XMLSchema#string

Cynthia White

http://www.w3.org/2001/XMLSchema#string

Hemant Sawnani

http://www.w3.org/2001/XMLSchema#string

John E Pascoe

http://www.w3.org/2001/XMLSchema#string

Joseph M McDonough

http://www.w3.org/2001/XMLSchema#string

Keith McConnell

http://www.w3.org/2001/XMLSchema#string

Oscar H Mayer

http://www.w3.org/2001/XMLSchema#string

Raouf S Amin

http://www.w3.org/2001/XMLSchema#string

P2860

Facilitators and Barriers to Noninvasive Ventilation Adherence in Youth with Nocturnal Hypoventilation Secondary to Obesity or Neuromuscular Disease

Standardisation of spirometry

Health care provider-delivered adherence promotion interventions: a meta-analysis.

Adherence with tobramycin inhaled solution and health care utilization.

Development and validation of the Pediatric Epilepsy Medication Self-Management Questionnaire.

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis

Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.

Evidence-based guideline summary: evaluation, diagnosis, and management of congenital muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Asso

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Electronic monitoring reveals highly variable adherence patterns in patients prescribed ivacaftor.

P304

939-945

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PPUL.23645

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27875025

http://www.w3.org/2001/XMLSchema#string

P921

birth defect

P932

6827716

http://www.w3.org/2001/XMLSchema#string